Amgen Inc. reports $36.75 billion revenue for fiscal year ended December 31, 2025, up 10%
Amgen Inc. reported revenue of $36.75 billion for the year ended December 31, 2025, an increase of 10% from the previous year ($33.42 billion).
For the same period it posted net income of $7.71 billion, up 88.5%, or $14.23 per diluted share (7.56 a year earlier).
That is a net margin of 21%.
On Sanad's AAOIFI Standard 21 screen, Amgen Inc. is currently compliant: interest-bearing debt is 21.8% of market capitalisation (limit 30%), and impure income is 1.1% of revenue (limit 5%).
Is Amgen Inc. halal?
See the full AAOIFI screening of Amgen Inc.
See the full AAOIFI screening of Amgen Inc.
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 13, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.